Tuesday, 01 March 2021 08:37

ProStrakan enters into £50 million agreement with AstraZeneca

Dr Tom Stratford CEO ProStrakan

Galashiels based ProStrakan Group and AstraZeneca have entered into an agreement for ProStrakan to acquire the rights to Moventig® (naloxegol) in the European Union (EU), Iceland, Norway, Switzerland and Liechtenstein.

Under the terms of the agreement, ProStrakan will make an upfront payment to AstraZeneca of $70 million (£50 million), to acquire the rights to sell and develop Moventig which is a treatment of opioid-induced constipation.

ProStrakan will make additional payments contingent on market access decisions in certain European markets, and will pay AstraZeneca tiered double-digit royalties on sales as well as sales milestones.

The transaction does not include the transfer of any AstraZeneca employees or facilities. Moventig is currently available in the UK, Ireland, Germany, the Nordics, Austria and Switzerland.

Luke Miels, Executive Vice President, Global Product and Portfolio Strategy, AstraZeneca, said: “This agreement is in line with our strategy to focus our resources within our three main therapy areas while unlocking value from the important medicines in our portfolio. ProStrakan’s significant expertise in the area of pain medication will ensure patients across Europe benefit from a first-in-class treatment. It complements our commitment along with Daiichi Sankyo to build the market and co-commercialise this important medicine in the US.”

Tom Stratford, Chief Executive of ProStrakan, said: “Moventig is an excellent fit for our oncology and pain-focused sales teams across Europe and opens up broader opportunities to serve both cancer and non-cancer chronic pain patients with this innovative, first-in-class therapy. This important medicine will complement our existing breakthrough cancer pain products, Abstral and PecFent, and, through our existing contact with oncology and pain specialists across the continent as well as other planned physician groups, I am confident that we can make Moventig available as an option to a broad range of patients who suffer opioid-induced constipation.”

ProStrakan Group is a subsidiary of Kyowa Hakko Kirin Co. Ltd.

If you liked that article you may be interested in these -

  • Scotland’s Best Outdoors Show Arrives at AECC Aberdeen Exhibition and Conference Centre (AECC) are looking forward to welcoming the ‘Scotland’s Best Outdoors’ show to the Centre this weekend (9th and 10th March 2013). This inaugural exhibition takes place in the AECC Arena and celeb...
  • Top ten tips on how to get ahead with social commerce Author: Rene Looper, Founder and Managing Director of Tuminds Ltd 1. Use your online audience as your marketers – customers trust people they know above brands, so it is important to encourage your target market to share your product content with ...
  • Spotlight on leaders at Chamber event The north-east’s business leaders will be urged to reflect upon the key characteristics the region’s next leaders must master at an event next month. Marianne Abib-Pech, former CFO of Shell Aviation turned writer and entrepreneur, is speaking at a...

   Subscribe-to-out-lists

* indicates required
Subscribe to city headline alert
The Soap Factory

The Soap Factory - the Aberdeen home of Flexible Working.

Aberdeen, Aberdeen City View details
Feb0916-19usd-program300x250

 

  • Facebook Page: 165971433539526
  • Twitter: SBNAberdeen
  • YouTube: aberdeenbusiness

Scottish Business News Network (SBNN)
111 Gallowgate
Aberdeen
AB25 1BU

T - 01224 619751

E - This email address is being protected from spambots. You need JavaScript enabled to view it.

If you liked that article you may be interested in these -

Emeli Sande’s musical success recognised with Arts & Business Scotland award

Read Full Article »